Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2006-08-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary objective: To show a 50% decrease in adipocytes adiponectin's expression in patients who developed LD versus those who did not developed LD during the first 3 months of a systemic therapy with corticosteroids
Secondary objectives: To look for differences in the mRNA expression of 11bHSD1, SREBP1c and PPARg in fat samples of patients before and after treatment with systemic corticosteroids and between LD+ and LD-patients To compare the fat morphology before and after treatment with glucosteroids
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
NCT01819883
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome
NCT01688349
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
NCT04583514
Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2
NCT04845165
Transcriptional Changes in Isolated Human Adipocytes During Obesity
NCT06907212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects: 32 HIV-free and Cushing disease-free adult patients for whom a prolonged treatment (³3months) with glucosteroids (³ 0.5 mg/kg/day) is initiated
Methods: At treatment initiation and 3 months after: comparison of fat sample mRNA expression of adipokines (adiponectin, leptin, IL6, TNFa), 11bHSD1, SREBP1c and PPARg, fat morphology and seric concentrations of adiponectin, leptin, IL6, sTNFR1 between patients LD+ and patients LD-. The diagnosis of LD will be performed by 3 experts using patients photographs
Aims of this study:
* To gain a better understanding of the pathophysiology of glucosteroids-induced LD
* To compare this pathophysiology to the one of HIV-associated LD for which the hypothesis of a local, cellular, hypercorticism has been put forward and for which related treatment have been prescribed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients with corticotherapy lasting more than 3 months
Samples and procedures
* Scanner, histomorphometry : at the inclusion and M3 visits
* whole blood samples, cytoponction : at the inclusion and M3 visits
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Samples and procedures
* Scanner, histomorphometry : at the inclusion and M3 visits
* whole blood samples, cytoponction : at the inclusion and M3 visits
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* starting therapy with prednisone
* corticosteroid therapy lasting more than 3 months
* baseline prednisone dosage \>= 0.5 mg/kg/d
Exclusion Criteria
* HIV +Pregnancy
* Recent weight lost (\> 5% of the usual weight)
* Therapy with glucocorticosteroids during the past 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence FARDET, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Saint-Antoine
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIRC 05147
Identifier Type: -
Identifier Source: secondary_id
P 051037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.